Abstract
The sodium-iodide symporter (NIS) is expressed by papillary (PTC) and follicular (FTC) thyroid carcinoma, and is essential for iodine uptake. We hypothesized that PTC and FTC with detectable NIS immunostaining would be more amenable to radioactive iodine (131I) treatment and follow a more benevolent course. To test this, we determined NIS expression by immunohistochemistry in 23 PTC, 9 FTC, and 12 benign thyroid lesions from children and adolescents. NIS expression was determined by two blinded examiners and graded as absent = 0, minimal = 1, moderate = 2, intense = 3, and very intense = 4. NIS was detected in 35% (eight of 23) of PTC, 44% (four of 9) of FTC, 25% (two of eight) of benign tumors, and 100% (four of four) of autoimmune lesions. The intensity of NIS expression was similar in PTC (0.61 ± 0.24), FTC (0.56 ± 0.24), and benign tumors (0.50 ± 0.33) but was more intense in autoimmune lesions (3.0 ± 0.7, p < 0.005). Distant metastases were found only among PTC with undetectable NIS (two of 15, 13%), and recurrence developed exclusively from PTC and FTC with undetectable NIS (four of 20, 20%versus zero of 12, p = 0.043). The dose of iodine 131 required to achieve remission in the five patients with PTC who had undetectable NIS (213.3 ± 53 mCi) was greater than that required by patients with similar age and extent of disease for whom NIS expression is unknown (109 ± 22 mCi, p = 0.06). We conclude that NIS expression is associated with a lower risk of recurrence for PTC and FTC of children and adolescents.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- NIS:
-
sodium-iodide symporter
- PTC:
-
papillary thyroid carcinoma
- FTC:
-
follicular thyroid carcinoma
- TTF-1:
-
thyroid transcription factor-1
- PAX-8:
-
paired-domain transcription factor-8
- GTPsα:
-
stimulatory alpha subunit of guanosine triphosphate binding protein
- ret/PTC:
-
rearrangement of ret protooncogene
- MACIS:
-
metastasis-age-completeness-of-resection-invasion-size
- Tg:
-
thyroglobulin
References
Mitchell AM, Manley SW, Morris JC, Powell KA, Bergert ER, Mortimer RH 2001 Sodium iodide symporter (nis) gene expression in human placenta. Placenta 22: 256–258
Nakamoto Y, Saga T, Misaki T, Kobayashi H, Sato N, Ishimori T, Kosugi S, Sakahara H, Konishi J 2000 Establishment characterization of a breast cancer cell line expressing Na+/I− symporters for radioiodide concentrator gene therapy. J Nucl Med 41: 1898–1904
Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Ludgate M, Weetman AP 1998 Regulation tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol Oxf 49: 517–523
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM 1998 Na+/I− symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83: 4102–4106
Pasca di Magliano M, Di Lauro R, Zannini M 2000 Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97: 13144–13149
Schmutzler C, Kohrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10: 393–406
Tanaka K, Otsuki T, Sonoo H, Yamamoto Y, Udagawa K, Kunisue H, Arime I, Yamamoto S, Kurebayashi J, Shimozuma K 2000 Semi-quantitative comparison of the differentiation markers sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR. Eur J Endocrinol 142: 340–346
Ros P, Rossi DL, Acebron A, Santisteban P 1999 Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 81: 389–396
Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S 1998 Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83: 2493–2496
Ringel MD, Anderson J, Souza SL, Burch HB, Tambascia M, Shriver CD, Tuttle RM 2001 Expression of the sodium iodide symporter thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 14: 289–296
Riedel C, Levy O, Carrasco N 2001 Post-transcriptional regulation of the sodium/iodide symporter (NIS) by thyrotropin. J Biol Chem 276: 21458–21463
Eng PH, Cardona GR, Previti MC, Chin WW, Braverman LE 2001 Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur J Endocrinol 144: 139–144
Arturi F, Russo D, Giuffrida D, Schlumberger M 2000 Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143: 623–627
Pomerance M, Abdullah HB, Kamerji S, Correze C, Blondeau JP 2000 Thyroid-stimulating hormone cyclic AMP activate p38 mitogen- activated protein kinase cascade: involvement of protein kinase A, rac1, reactive oxygen species. J Biol Chem 275: 40539–40546
Kogai T, Schultz JJ, Johnson LS, Huang M, Brent GA 2000 Retinoic acid induces sodium/iodide symporter gene expression radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA 97: 8519–8524
Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M 1999 Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141: 443–457
Spitzweg C, Morris JC 2000 The immune response to the iodide transporter. Endocrinol Metab Clin North Am 29: 389–398, viii
Spitzweg C, Joba W, Morris JC, Heufelder AE 1999 Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 9: 821–830
Ajjan RA, Watson PF, Findlay C, Metcalfe RA, Crisp M, Ludgate M, Weetman AP 1998 The sodium iodide symporter gene its regulation by cytokines found in autoimmunity. J Endocrinol 158: 351–358
Thomas CG, Croom RD 1987 Current management of the patient with autonomously functioning nodular goiter. Surg Clin North Am 67: 315–328
Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR, Fischer AH, Mazzaferri EL 1998 An immunohistochemical study of Na+/I− symporter in human thyroid tissues salivary gland tissues. Endocrinology 139: 4416–4419
Lin JD, Chan EC, Chao TC, Chen KT, Hsueh C, Ho YS, Weng HF 2000 Expression of sodium iodide symporter in metastatic follicular human thyroid tissues. Ann Oncol 11: 625–629
Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, Goellner JR, Morris JC 1999 Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163: 495–504
Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A, Onaya T 1998 Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101: 1296–1300
Wapnir IGR, Dohan O, Amenta P, Carrasco N 2001 NIS expression in thyroid cancer. Proc ASCO 20: 336b
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M 1999 Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84: 3228–3234
Feinmesser R, Lubin E, Segal K, Noyek A 1997 Carcinoma of the thyroid in children—a review. J Pediatr Endocrinol Metab 10: 561–568
Zimmerman D 1997 Thyroid neoplasia in children [see comments]. Curr Opin Pediatr 9: 413–418
Welch-Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL 1998 Clinical features associated with metastasis recurrence of differentiated thyroid cancer in children, adolescents young adults. Clin Endocrinol (Oxf) 49: 619–628
McClellan DR, Francis GL 1996 Thyroid cancer in children, pregnant women, patients with Graves' disease. Endocrinol Metab Clin North Am 25: 27–48
Waldmann V, Rabes HM 1997 Absence of G(s)alpha gene mutations in childhood thyroid tumors after Chernobyl in contrast to sporadic adult thyroid neoplasia. Cancer Res 57: 2358–2361
Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children young adults. J Clin Endocrinol Metab 85: 1170–1175
DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71: 414–424
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050–1058
Hedinger C, Williams ED, Sobin LH 1989 The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63: 908–911
Cho JY, Leveille R, Kao R, Rousset B, Parlow AF, Burak WE, Mazzaferri EL, Jhiang SM 2000 Hormonal regulation of radioiodide uptake activity Na+/I− symporter expression in mammary glands. J Clin Endocrinol Metab 85: 2936–2943
Cho JY, Xing S, Liu X, Buckwalter TL, Hwa L, Sferra TJ, Chiu IM, Jhiang SM 2000 Expression activity of human Na+/I− symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 7: 740–749
Hung W 1992 Nodular thyroid disease thyroid carcinoma. Pediatr Ann 21: 50–57
Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75: 714–720
Wartofsky L 2000 An approach to the management of patients with scan negative, thyroglobulin positive, differentiated thyroid carcinoma. In: Wartofsky L (ed) Thyroid Cancer: A Comprehensive Guide to Clinical Management. Humana Press, Totowa, NJ, pp 251–261
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, U.S.A., under WU # 00-6501.
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the opinions of the Uniformed Services University of the Health Sciences, the Department of the Army, or the Department of Defense.
Rights and permissions
About this article
Cite this article
Patel, A., Jhiang, S., Dogra, S. et al. Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents. Pediatr Res 52, 737–744 (2002). https://doi.org/10.1203/00006450-200211000-00021
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200211000-00021
This article is cited by
-
The U-Shaped association between age and distant metastasis in patients with papillary thyroid carcinoma
Endocrine (2024)
-
RETRACTED ARTICLE: Inhibition of microRNA-875-5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium–iodide symporter
Journal of Endocrinological Investigation (2020)
-
Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid Carcinoma
Nuclear Medicine and Molecular Imaging (2014)
-
No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis
European Journal of Nuclear Medicine and Molecular Imaging (2008)
-
Distribution of Na+/I– Symporter in Thyroid Cancers in an Iodine‐deficient Population: An Immunohistochemical Study
World Journal of Surgery (2007)